Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market

NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company") announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of...
September 02, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio and Hercules Capital Amend Loan and Security Agreement

NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics,...
August 19, 2019 02:00 ET | Source: Motif Bio plc

NIH to Evaluate Iclaprim Activity against Listeria

NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the...
August 01, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio and Hercules Capital Amend Loan and Security Agreement

NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its...
July 26, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio Confirms Receipt of Deficiency Notice from Nasdaq

NEW YORK, July 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has...
July 26, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim

NEW YORK, July 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S....
July 19, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio Announces Receipt of Deficiency Notice from Nasdaq

NEW YORK, July 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has...
July 15, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio Submits Meeting Request and Package to the U.S. FDA for Iclaprim

NEW YORK, July 15, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has...
June 24, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio Presents New Iclaprim Data at ASM Microbe 2019

NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today reported that new...
June 06, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes

NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the...